Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DII235 in adults with elevated lipoprotein(a)
CTR20260186Phase 2Active
- Sponsor
- Novartis
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BW-20829 in lipoprotein(a) hyperlipoproteinemia (Lp(a)), atherosclerotic disease, type 2 diabetes mellitus (T2DM), sponsored by Novartis. Started Mar 2026; status: active.
02
Drugs
BW-20829
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))atherosclerotic diseasetype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20260186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260186.